Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Asset Utilization Ratio (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Asset Utilization Ratio for 14 consecutive years, with 0.64 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Utilization Ratio fell 0.98% year-over-year to 0.64, compared with a TTM value of 0.64 through Dec 2025, down 0.98%, and an annual FY2025 reading of 0.69, up 1.38% over the prior year.
  • Asset Utilization Ratio was 0.64 for Q4 2025 at Neurocrine Biosciences, down from 0.66 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.66 in Q2 2025 and bottomed at 0.4 in Q2 2021.
  • Average Asset Utilization Ratio over 4 years is 0.58, with a median of 0.62 recorded in 2023.
  • The sharpest move saw Asset Utilization Ratio tumbled 40.77% in 2021, then soared 33.29% in 2024.
  • Year by year, Asset Utilization Ratio stood at 0.4 in 2021, then soared by 54.54% to 0.62 in 2023, then grew by 4.95% to 0.65 in 2024, then decreased by 0.98% to 0.64 in 2025.
  • Business Quant data shows Asset Utilization Ratio for NBIX at 0.64 in Q4 2025, 0.66 in Q3 2025, and 0.66 in Q2 2025.